Clinical Trial Update: Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and tolerability of AZD1152 in combination with low-dose cytarabine for acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZD1152 (barasertib)
• CYTARABINE (CYTARABINE)

Snippet

Sponsor: AstraZeneca | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: COMPLETED